Please amend the application as follows:

In the Claims:

For the Examiner's convenience, Applicants present all pending claims with status indicators.

Claims 1 to 63. (Canceled)

Claim 64. (Withdrawn) A use of a first allergen or of an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said first allergen, for preparing a pharmaceutical composition that is useful for treating or preventing an allergy caused by a second allergen different from the first allergen.

Claim 65. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a cystine protease of an acarid.

Claim 66. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a cystine protease of an acarid, and said second allergen is not a cystine protease of said acarid.

Claim 67. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is a cystine protease of a mite.

Claim 68. (Withdrawn) The use as claimed in claim 64, wherein said first allergen is at least one peptide epitope of a cystine protease.

Claim 69. (Withdrawn) The use as claimed in claim 68, wherein said first allergen is at least one peptide epitope of a cystine protease having the sequence SEQ ID NO: 2.

Claim 70. (Withdrawn) The use as claimed in claim 68, wherein said first allergen is a peptide or a mixture of peptide which are chosen from the group consisting of the peptides having the sequence SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

Claim 71. (Withdrawn) The use as claimed in claim 67, wherein said first allergen is natural and is obtained by extraction of *D. Pteronyssinus* and/or *D. Ferinae* from mites

Claim 72. (Withdrawn) The use as claimed in claim 67, wherein said second allergen is not a cystine protease of said mite.

Claim 73. (Withdrawn) A method for making a pharmaceutical composition that is useful for treating an allergy caused by a first allergen comprising the steps of :

providing a second allergen different from said first allergen or an isolated nucleic acid molecule comprising at least one polynucleotide sequence encoding said second allergen; and

preparing said pharmaceutical composition from said second allergen or said isolated nucleic acid molecule.

Claim 74. (Currently Amended) An anti-allergic pharmaceutical composition comprising

(a) an acarid allergen ~~comprising~~ consisting of

~~i. the allergen encoded by the polynucleotide of SEQ ID NO:1,~~

~~ii. the allergen as shown in SEQ ID NO:2,~~

i. ~~iii.~~ the allergen as shown in SEQ ID NO:3,

ii. ~~iv.~~ the allergen as shown in SEQ ID NO:4, and/or

iii ~~v.~~ the allergen as shown in SEQ ID NO:5,

(b) an antihistamine selected from the group consisting of brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxizine, ketotifene, loratidine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochlorate and doxylamine,

(c) an inhibitor of histamine synthesis, wherein the inhibitor comprisinges an inhibitor of histidine decarboxylase, and

(d) a pharmaceutically acceptable carrier.

Claim 75. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is *D.Pteronyssinus*.

Claim 76. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is *D.Farinae*.

Claim 77. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is a cystine protease.

Claim 78. (Previously Presented) The pharmaceutical composition of claim 82, wherein the inhibitor of histidine decarboxylase is tritoqualine.

Claim 79. (Currently Amended) A method for ~~reducing~~ treating an allergic hypersensitivity reaction comprising administration of the pharmaceutical composition of claim 74 to a subject.

Claim 80. (Currently Amended) The method of claim 79, wherein ~~reducing~~ the allergic hypersensitivity reaction ~~treats allergic hypersensitivity~~ is reduced in the subject.

Claim 81. (Previously Presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is present in an amount of 1 to 1500 micrograms or 10 to 150 micrograms.

Claim 82. (Previously Presented) The pharmaceutical composition of claim 74, wherein the antihistamine is present in an amount of 1 to 2000 milligrams or 5 to 200 milligrams.

Claim 83. (Currently Amended) The pharmaceutical composition of claim 74, wherein the inhibitor of histamine synthesis is present in an amount of between 1 to 2000 milligrams, 5 to 200 milligrams or 10 to 300 milligrams.